Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, Masahiro; Yano, Seiji; Giaccone, Giuseppe; Tamura, Tomohide; Nakagawa, Kazuhiko; Douillard, Jean‐Yves; Nishiwaki, Yutaka; Vansteenkiste, Johan; Kudoh, Shinzoh; Rischin, Danny; Eek, Richard; Horai, Takeshi; Noda, Kazumasa; Takata, Ichiro; F. Smit, Egbert; D. Averbuch, Steven; Macleod, Angela; Feyereislova, A.; Dong, Rui-Ping; Baselga, José

doi:10.1200/jco.2003.10.038

Public

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • May 20, 2003

Authors:

Masahiro Fukuoka

Seiji Yano

Giuseppe Giaccone

Abstract

PURPOSE: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: This was a r...

Subject

Gefitinib

Medicine

Tolerability

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!